H.C. Wainwright Reiterates Buy Rating on Axsome Shares
H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $42.00 ...
Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...
H.C. Wainwright Keeps Their Buy Rating on Disc Medicine (IRON)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine (IRON – Research Report) today and set a price target of $118.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) Given Buy Rating at HC Wainwright
HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $18.00 price ...
BTCS Inc. To Participate In Fireside Chat With Blockdaemon Hosted By H.C. Wainwright
BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the“Company”), a leader in blockchain infrastructure and technology, has announced its ...
Fintel on MSN4d
HC Wainwright & Co. Downgrades CECO Environmental (CECO)
Fintel reports that on January 17, 2025, HC Wainwright & Co. downgraded their outlook for CECO Environmental (NasdaqGS:CECO) ...
bovnews1d
H.C. Wainwright Just Reiterated Microbot Medical Inc (MBOT) Stock—What Does This Mean for Investors?
Microbot Medical Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 51.85%. The profit margin, also known as the revenue ratio or gross profit ratio, ...
Nasdaq23d
MetaVia initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...
Nasdaq14d
H.C. Wainwright ups Sana target after ‘best case scenario’ data
H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...
Seeking Alpha27d
RAPT upgraded at H.C. Wainwright on China licensing deal
RAPT Therapeutics (NASDAQ:RAPT) shares rose on Thursday after H.C. Wainwright upgraded the immunology-focused biotech to Buy from Neutral based on the company's recent licensing deal with China's ...
Yahoo Finance26d
Palvella Therapeutics initiated with a Buy at H.C. Wainwright
https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-10-from-12-at-bofa H.C. Wainwright initiated coverage of Palvella Therapeutics ...